GlassScriptPhysician profile
Kenneth D Rappaport
NPI 1114916368
$2,062.52
in general payments reported to CMS, 2019-2025
16 companies · $474 in 2025
The $474 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $137 · 2021: $256 · 2022: $133 · 2023: $390 · 2024: $497 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,212 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,211.60 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $370.41 | 2019-2024 | Eylea Hd |
| Edwards Lifesciences Corporation | $287.60 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Novartis Pharmaceuticals Corporation | $272.29 | 2019-2021 | |
| Astellas Pharma US INC | $244.78 | 2024-2025 | Izervay |
| Apellis Pharmaceuticals, INC. | $171.81 | 2022-2024 | Syfovre |
| Lilly USA, LLC | $159.57 | 2023-2025 | Zepbound, Mounjaro |
| Cardinal Health 110 LLC | $150.00 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $107.32 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.16 | 2023 | Jardiance |
| Corcept Therapeutics | $86.05 | 2022-2023 | Korlym |
| Genentech USA, INC. | $23.41 | 2021 | |
| Abbvie INC. | $20.03 | 2022 | |
| Novo Nordisk INC | $19.72 | 2024 | Rybelsus, Ozempic |
| Biohaven Pharmaceutical Holding Company LTD. | $18.12 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.49 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $13.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Rappaport listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.